DUBLIN, Ireland--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/3f9d45/currently_druggabl) has
announced the addition of the "Currently Druggable in Colorectal Cancer: A Drug
Target Competitive Analysis" report to their offering.
Not surprisingly, an increasing number of companies have turned their attention
to the cancer targeted therapy market, undoubtedly trying to emulate the
blockbuster status that several brands have already achieved.
This report aims to analyze the current and future potential of colorectal
cancer pipeline by examining key fundamentals across the entire pipeline of drug
candidates. the author has identified three fundamental dimensions to outline
the competitive landscape within the pharmaceutical industry; compound type,
therapy area and target type.
This report is written for you to identify your competition and understand which
targeting strategies are at work within colorectal cancer drug development. It
allows you to pin-point which competitors drugs' clinical out-come may have
bearing on your own drug development and who are developing sequels to
successful drugs. This report also helps you to locate white-spots in the
competitive landscape, giving you little or no competition. Conversely it may
reveal unexpected competition for you.
Drug targets are the critical link between drugs and their role in the treatment
of medical disorders. BioSeeker has surveyed the colorectal cancer field and
identified 120 drug targets belonging to 156 drugs. This report, Currently
Druggable in Colorectal Cancer: A Drug Target Competitive Analysis is an open
landscape of resources to build, fuel, and drive your scientific competitive
vehicle for the advancement of colorectal cancer drugs.
In the report, the author reports on 105 unique drug target combinations, each
comprised of a different collection or mix of individually defined targets, for
156 colorectal cancer drugs. The highest degree of distinctiveness among the
cancer drugs is achieved by sorting each of them according to drug target mix,
compound type and R&D approach. At the same time we are also identifying peer
groups of drugs, that is, drugs we consider suitable for head-to-head comparison
during drug development.
To fuel the scientific and competitive thinking, the author opens the gate into
the presence and relevance of protein-protein interactions between identified
targets of colorectal cancer drugs. No less than 231 target-target interactions
were recognized among and between 87 of the 120 included colorectal cancer drug
targets.
Why You Should Own Your Own Copy of this Report:
* 300 pages, with more than 50 different tables and figures. Includes more than
1,000 active links to drug target related resources on the Internet
* A 156 colorectal cancer drugs analysis, under development by 95 investigators
* 120 unique, in-depth, drug target validating profiles, highlighting twelve
themes about the drug target, i.e. protein-protein interaction with other
colorectal cancer drug targets, pursued cancer indications, drugs under
development, presence in the Cancer Genome Project etc.
* A unique drug target combination breakdown of colorectal cancer drugs into R&D
approaches
* Unique drug-protein target interactome- and protein-protein interactome of
drug targets analysis
* Pathway profiling of colorectal cancer drug targets
* Compound strategies based on sub-cellular localization of drug targets
* Expression levels of identified drug targets in malignant colorectal cancer
tissue
* Structure based drug design in colorectal cancer
* Pin-point which competitor drugs' clinical out-come may have bearing on your
own drug development
* Who are working on sequels to blockbuster drugs?
* Locate white-spots in the competitive landscape, giving you little or no
competition
In all, this report is a serious reference for any professional interested in
the development of oncology drug targets and the selection/validation of
targeting strategies.
Key Topics Covered:
* Executive Summary
* About Cancer Highlights
* Methodologies
* Table of Contents
* How to Use this Report
* Compound Strategies based on Sub-Cellular Localization of Colorectal Cancer
Drug Targets
* The Cancer Genome Project and Colorectal Cancer Targets
* Expression Levels of Identified Drug Targets in Colorectal Cancer Tissue
* Pathway Analysis of Colorectal Cancer Drugs
* Target-Target Interactions among Identified Colorectal Cancer Targets
* Structure-based Drug Design in Colorectal Cancer is Stimulated by Available
Structure Data on Biological Targets
* Drug Target Profiles of Colorectal Cancer Drugs
* The Drug-Target Interactome
* The Progression and Maturity of Colorectal Cancer Targets
* Targets by R&D Approach in Colorectal Cancer
* Colorectal Cancer Targets by Companies
* Disclaimer
* Drug Index
* Company Index
For more information visit
http://www.researchandmarkets.com/research/3f9d45/currently_druggabl
Research and Markets
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
Copyright Business Wire 2009
